Press archive
The 20 recent news
09/02/08, Cardiology/Hematology Bayer Submits Recombinant Human Thrombin for European Approval Recothrom® would be the first recombinant human thrombin for use as a topical aid to surgical hemostasis in Europe more
08/31/08, Thrombosis Rivaroxaban Phase II Data in ACS to be Presented at AHA Congress in November 2008 First data presentation from large dose-finding trial involving about 3,500 patients / Acceleration of clinical development in acute coronary syndrome planned more
08/21/08, Oncology New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer Enrollment initiated in international phase III study more
08/19/08, Research & Development Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration Study patients, on average, received only two additional doses following a 12-week fixed dosing period more
08/19/08, Gynecology/Andrology Bayer Schering Pharma to support USAID with contraceptives for family planning programs Access to family planning for more than 8 million women in developing countries / 110 million cycles of oral contraceptives to be provided each year more
08/07/08, Research & Development Bayer acquires Preclinical Anti-cancer Program from Nycomed Company assuming full development and commercialization rights more
07/30/08, Bayer HealthCare Bayer continues its success Sales up 3.6 percent to EUR 8,511 million / EBITDA before special items increases by 5.0 percent to EUR 1,896 million / EBIT before special items improves by 5.3 percent to EUR 1,248 million / Full-y... more
07/30/08, Thrombosis Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S. Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues attribut... more
07/28/08, Oncology Nexavar Approved for Treatment of Liver Cancer in China Nexavar is First Approved Systemic Therapy to Treat the Disease more
07/25/08, Levitra Study Confirms that Levitra® on demand is Effective in Patients with ED after Nerve-sparing Prostatectomy Berlin, July 25, 2008 – A study published in the European Urology journal demonstrated that Levitra® (vardenafil, HCI) is highly efficacious in men with erectile dysfunction (ED) even shortly ... more
07/25/08, Research & Development Bayer’s Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU Final approval from the European Commission expected within the next few months more
07/25/08, Bayer Schering Pharma Andreas Fibig named new Chairman of the Board of Management of Bayer Schering Pharma Dr. Bernd Metzner to become new Board member of Bayer’s pharmaceuticals subsidiary / Arthur Higgins and Werner Baumann to refocus on their leadership roles in the Bayer HealthCare subgroup foll... more
07/25/08, Avelox Bayer welcomes the proposed EMEA labeling changes for moxifloxacin which are consistent with existing guidelines for appropriate use of fluoroquinolone antibiotics Leverkusen, July 25, 2008 – Bayer is pleased to announce that today the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) proposed a labeling change... more
07/24/08, Oncology Nexavar Study Demonstrates Significant Improvement in Overall Survival in Patients with Liver Cancer Nexavar is First Approved Systemic Therapy to Treat the Disease more
07/10/08, Worldnews Geri Winkler becomes the first diabetic to conquer the Seven Summits Adventurer reaches the peak of Mount McKinley (Denali) in Alaska more
07/08/08, Primovist Primovist® approved in the U.S. for the Detection and Characterization of Liver Lesions First organ-specific diagnostic agent approved in the U.S. in more than a decade more
07/08/08, Animal Health Pharmaceuticals for the global cattle market gain further significance Bayer Animal Health at the XXVth World Buiatrics Congress in Budapest more
07/02/08, Bayer HealthCare Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology Significantly Strengthens Consumer Care Division’s Business in High Growth Chinese OTC Market more
07/02/08, Cardiology/Hematology Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen’s novel biotechnology research platform more
06/30/08, Research & Development Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death Rivaroxaban shows superior efficacy to enoxaparin for this clinical outcome with a comparable safety profile / Pre-specified analysis of pooled data from RECORD 1-3 studies involving nearly 10,000 pa... more
